Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
It is demonstrated that the amount of PEG-lipid used in the LNP formulation has a significant impact on humoral immune responses to mRNA-LNP vaccines in mice and can impact memory B cell responses.
Abstract
mRNA - lipid nanoparticle (LNP) vaccines developed against SARS-CoV-2 are a transformative technology and saved millions of lives during the COVID-19 pandemic. In this vaccine platform, LNPs function as both a delivery agent and a powerful adjuvant. However, the relationship between LNP composition and adjuvanticity is not fully understood, hindering future vaccine design.
In this study, we focus on the impact of the Polyethylene-glycol conjugated lipid (PEG-lipid) which is one of the four standard lipids used to make LNPs. PEG-lipids are known to give stability to nanoparticles in solution, control particle size, and impact circulation half-life. We designed mRNA-LNP vaccines that encode SARS-CoV-2 spike as a model antigen, and we modulate the amount of PEG-lipid within the LNP. A comparative vaccination study was performed using BALB/c mice.
We demonstrate that the amount of PEG-lipid used in the LNP formulation has a significant impact on humoral immune responses to mRNA-LNP vaccines in mice and can impact memory B cell responses.
These findings support the rational design of novel LNPs to create more tailored and effective mRNA vaccines against both existing and emerging infectious pathogens.
NIAID, R01AI153064
Vaccines and Immunotherapy (VAC)
With the rapid advancement of mRNA vaccines, lipid nanoparticles (LNPs) have emerged as pivotal carriers and adjuvants for non-mRNA vaccine modalities, driven by their superior nucleic acid delivery efficiency and intrinsic self-adjuvanting properties. In this study, we systematically evaluated various formulation stra...
Ning Luan, Han Cao, Xiaolong Zhang et al.· bioRxiv· 0 citations
The recent success of RNA/lipid nanoparticle (LNP)-based vaccine formulations in the clinic against SARS-CoV-2 and RSV has highlighted the potential of this platform. While RNA/LNP vaccines share the fundamental principle of using lipid nanoparticles to deliver RNA molecules into host cells to induce antigen expres...
Hiva Azizi, Tyler M. Renner, Gerard Agbayani et al.· Scientific Reports· 0 citations
This synthesis aims to guide formulation scientists, clinician‐scientists, and regulatory professionals in advancing the next generation of LNP‐based precision nanomedicines by linking molecular lipid design to manufacturing scalability, long‐term safety, and equitable access.
T. Ikrar, Wachyudi Muchsin, Alfi Sophian· European Journal of Lipid Sc...· 0 citations
This review provides an integrated overview of recent advances in mRNA-LNP vaccines, covering mRNA molecular engineering, LNP composition and delivery mechanisms, immune responses, clinical progress, and current developmental challenges.
Zhi-Neng Wu, Jinghu Lou, Yi Cheng et al.· Molecular Biomedicine· 0 citations
Rational design of adjuvants that simultaneously increase immunogenicity and reduce reactogenicity remains a challenge for protein vaccine development. Conventional adjuvants, like aluminum salts, and oil-in-water emulsions (like MF59, AS03, and AddaVax), work well to increase antibody titers but have variable abilit...
J. Felgner, Jenny E. Hernandez-Davies, Andriy V. Yeromin et al.· npj Vaccines· 0 citations
This study successfully develops an optimized formulation with reduced hepatic off-target effects, which holds great promise for the intramuscular delivery of circRNA-based vaccines and therapeutics.
Jie Yang, Yi-Jia Hao, Si-Ying Long et al.· Lab on a Chip· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.